

Company Fact Sheet

Pevion Biotech at a glance

- Privately-owned vaccine development company with headquarters in Ittigen (Bern), Switzerland
- Product pipeline focusing on unmet medical needs in the field of mucosal infections and cancer
- Vaccine candidates based on clinically and commercially validated carrier & adjuvant technology (virosoemes)
- Industrial partnerships established, one product successfully out-licensed
- Technology and product portfolio protected by an extensive patent portfolio of 14 patent families and more than 90 granted patents
- Experienced management and personnel guarantee state-of-the-art development

COMPANY

Pevion Biotech is a Swiss development company active in one of the fastest growing segments in the pharmaceutical industry, the vaccine market (CAGR approx. 30%). Based on its clinically and commercially validated virosome technology, Pevion Biotech has brought forth a well-focused product pipeline filled with vaccine candidates that will meet major unmet medical needs. The company has the expertise and capability to develop its candidate vaccines according to industry standards, including a state-of-the-art and industrial scalable GMP manufacturing process.

BUSINESS STRATEGY



Pevion Biotech develops efficient and safe subunit vaccines based on its proprietary adjuvant and carrier technology (virosoemes). The company aims to maximize and leverage the potential of its virosome technology by developing vaccines for indications with high market potential and to license the technology for distinct indications and applications. Pevion Biotech develops its candidate vaccines up to clinical Phases I/II, using established development and manufacturing processes. It then licenses them to partners for further development, registration, marketing and sales. Pevion Biotech's most advanced product has already been out-licensed.

TECHNOLOGY

Pevion Biotech's virosome technology is the only regulatory and market-approved vaccine carrier system for the delivery of immunologically active substances. This predominantly synthetic carrier is broadly applicable to almost any given antigen, including peptide or protein antigens. Three virosome-based vaccines (Epaxal® against hepatitis A, Inflexal® V and Invivac® against influenza) have been registered in Europe and other countries including Canada and Australia. The technology is distinguished by its excellent versatility, immunogenicity and safety profile. The application of this established and validated technology allows a faster time to market and a reduced developmental risk for novel vaccine candidates.

PRODUCT PIPELINE

Pevion Biotech is developing prophylactic vaccines against mucosal infections and cancer. It is concentrating its efforts and expertise on four most promising candidate vaccines against breast cancer, Candida, respiratory syncytial virus (RSV), and influenza. The Candida vaccine has recently entered a Phase I trial, the other two vaccine candidates will enter clinical development in late 2010 and 2011. The safety aspect of Pevion Biotech's virosoemes gives its RSV and broadband influenza vaccines a competitive edge over other approaches, since the major target populations are elderly and infants. These vaccines have the potential to become best-in-class products. The Candida and RSV vaccines even have first-in-class opportunities since no prophylactic treatments are currently available. Pevion Biotech's vaccine candidates have a market potential of more than CHF 1bn each.

Discovery	Optimiz.	Preclinical	Phase I	Phase II	Phase III
Candida PEV7					
RSV PEV4					
Broadband influenza PEV8					
Breast cancer PEV6					
Malaria - Partnered 					
HIV - Platform out-licensed 					

RECENT MILESTONES

- A Phase I study in cancer patients showed that the breast cancer vaccine PEV6 is well tolerated and induced a good immune response in cancer patients aged 55-84 with as little as 10 µg peptide per dose.
- A human proof of concept for the lyophilized form of virosome-based vaccines was reached in a Phase Ib study in adults and children. The lyophilized vaccine with extended shelf life proved safe and immunogenic.
- The Candida vaccine entered clinical development in February 2010.
- The RSV vaccine reached proof of concept in animals. Mice and cotton rats were protected against a live virus challenge, and no pathological events were detected.
- The broadband influenza vaccine reached proof of concept in animals and protected against a live virus challenge.
- The company licensed its most advanced product candidate (malaria vaccine) to Mymetics Corp.

FINANCIAL SUMMARY

In its initial years the company was supported by its two founding companies (Bachem Holding, Berna Biotech/Crucell), which provided a total of CHF 20 million as a start-up capital. The company raised an additional CHFm 35 in a second financial placement in 2007. The current shareholders include Bachem Holding, BZ Bank, BB Biotech Venture II and Core Capital Partners.

PEOPLE AT PEVION BIOTECH

The company comprises 25 highly skilled and motivated employees. The team is led by an experienced management team and board, who combine all necessary skills and expertise for successful vaccine development. The skills are complemented by a global scientific network of renowned experts in the field and prestigious academic research institutions. This network gives Pevion Biotech prime access to cutting-edge science, disease-specific know-how and additional specimens and research materials.

To request further information, please contact. Dr. Julian Wagner, BD Manager julian.wagner@pevion.com, Tel: +41 31 550 44 13

Pevion Biotech Ltd.
 Worblentalstrasse 32
 CH-3063 Ittigen (Switzerland)
 Phone: +41 (31) 550 4444
 Fax: +41 (31) 550 4445
 Email: info@pevion.com
 URL: www.pevion.com

Management Team Pevion Biotech	
Dr. T. Stauffer	CEO
Dr. C. Spyr	Head of Clinical Development & Project Management
Dr. M. Amacker	Head of Process Development & Manufacturing
Dr. C. Moser	Head of Research

